PSTV Form 3 — Kyle Guse Listed as Director With No Holdings

Rhea-AI Filing Summary

PLUS THERAPEUTICS, Inc. (PSTV) Form 3 shows an initial Section 16 filing by Kyle Guse dated 04/18/2025 listing his role as a Director and providing a company address in Austin, TX. The filing reports 0 shares of Common Stock owned directly and discloses no derivative securities. The form is signed by an attorney-in-fact on 08/15/2025.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Guse Kyle

(Last) (First) (Middle)

C/O PLUS THERAPEUTICS INC.

4200 MARATHON BOULEVARD, SUITE 200

(Street)

AUSTIN TX 78756

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/18/2025

3. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Andrew Sims, attorney-in-fact	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the PSTV Form 3 filed for Kyle Guse disclose?

The filing discloses Kyle Guse as a Director of PLUS THERAPEUTICS (PSTV) with 0 shares of Common Stock beneficially owned and no derivative holdings.

When is the event date listed on the PSTV Form 3?

The event date reported on the form is 04/18/2025.

Who signed the Form 3 for Kyle Guse and when?

The form shows a signature by /s/ Andrew Sims, attorney-in-fact dated 08/15/2025.

Does the Form 3 report any options, warrants, or convertible securities for PSTV?

No. Table II lists no derivative securities; the filing reports no exercisable or convertible instruments.

What is the reporting person's address on the PSTV Form 3?

The address listed is 4200 Marathon Boulevard, Suite 200, Austin, TX 78756 (c/o PLUS THERAPEUTICS INC.).